The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy

Zhang, Lilong; Zhao, Kailiang; kuang, Tianrui; Wang, Kunpeng; Chai, Dongqi; Qiu, Zhendong; Liu, Rongqiang; Deng, Wenhong; Wang, Weixing

doi:10.1186/s12885-023-10570-6

BMC Cancer

Table 1 Main characteristics of the studies included

From: The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy

Study	Study region	Study design	Study period	Sample size	Male/ Female	Cancer types	Treatment	Follow-up duration	Cut-off	Out-come	NOS
Zhang et al. 2022 [15]	Xi'an, China	R	2010- 2017	615	469/146	GC	Surgery	-	39.8	OS (M) DFS (M)	8
Horino et al. 2022 [18]	Kumamoto, Japan	R	04/2005–06/2019	813	464/349	CRC	Surgery	-	43.1/13.2^e	OS (M) DFS (M)	7
He et al. 2022 [19]	Nanjing, China	R	01/2009–03/2016	358	284/74	GC	Surgery	101 (2–166)^a	40.5	OS (M)	6
Deng et al. 2022 [20]	Fuzhou, China	R	01/2012–12/2016	360	194/166	CRC	Surgery	65 (3–110)^a	36.3	OS (M) DFS (M)	7
Tan et al. 2022 [23]	Nanning, China	R	09/2013–07/2018	158	126/32	EC	Surgery	-	31.2	OS (M)	6
Xie et al. 2022 [25]	Nanning, China	R	2012- 2014	662	408/254	CRC	Surgery	63 (1–80)^a	31.6/24.4^e	OS (M) PFS (U)	7
Kusunoki et al. 2022 [26]	Mie, Japan	R	02/2005–11/2011	298	171/127	CRC	Surgery	39.7 ± 29.0^c	20.5	OS (M) DFS (M)	6
Pian et al. 2022 [17]	Suwon, Korea	R	06/2009–06/2018	132	88/44	CRC	Surgery	-	70.4	OS (M) DFS (U)	7
Ruan et al. 2022 [24]	Multicenter, China	P	06/2012–12/2019	691	-	GM	Cancer Sarcopenia	43.7^b	18.4	OS (M)	8
Wu et al. 2022 [16]	Fuzhou, China	R	2016- 2019	97	58/39	CC	Surgery	20 (3–70)^a	31.8	OS (M) DFS (M)	6
Qian et al. 2022 [31]	Zhengzhou, China	R	2017- 2020	65	55/10	HCC	Camrel-izumab	-	34.7	OS (M)	6
Chen et al. 2022 [32]	Fuzhou, China	R	01/2013–04/2019	636	385/281	CRC	Surgery	59.3(40.6–80.4)^d	40.0	OS (M)	7
Tsai, et al. 2021 [22]	Taiwan, China	R	01/2008–12/2017	372	336/36	OCC	Surgery	58.5 (2–126)^a	33.6	OS (M) DFS (M)	6
Yin et al. 2021 [21]	Mie, Japan	R	1992–2011	620	424/196	GC	Surgery	52.8 ± 39.9^c	30.0	OS (M)	8
Shibutani et al. 2019 [29]	Osaka, Japan	R	2008–2016	159	87/72	CRC	Chemo-therapy	21.6 (1.2–94.0)^a	28.9	OS (M)	7
Topkan et al. 2019 [28]	Adana, Turkey	R	01/2007–12/2017	141	111/30	PC	Chemor-adiotherapy	14.4 (3.2–74.2)^a	25.3	OS (U) PFS (U)	7
Barth et al. 2019 [27]	Graz, Austria	R	12/2003–10/2015	429	236/193	PC	Surgery or chemotherapy	-	43.5	CSS (M)	7
Feng et al. 2014 [30]	Hangzhou, China	R	01/2006–12/2008	293	259/34	EC	Surgery	-	18.0	CSS (M)	6

P Prospective cohort study, R Retrospective study, GC Gastric cancer, CRC Colorectal cancer, EC Esophageal cancer, HCC Hepatocellular carcinoma, PC Pancreatic cancer, CC Cholangiocarcinoma, OCC Oral cavity cancer, GM Gastrointestinal malignancy, including 245 patients with gastric cancer, 270 patients with colorectal cancer, 145 patients with esophageal cancer, and 31 patients with hepatobiliary cancer. M Multivariate analysis, U Univariate analysis
^amedians with ranges
^bmedians
^cMean ± standard deviation
^dmedian and interquartile range
^emale/female

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com